All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

eravacycline dihydrochloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives	5294	1334714-66-7

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: eravacycline dihydrochloride xerava TP-434

Eravacycline is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains. Molecular weight: 558.56 Formula: C27H31FN4O8 CLOGP: 0.01 LIPINSKI: 3 HAC: 12 HDO: 6 TPSA: 193.73 ALOGS: -2.82 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	2.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.71 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.18 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 20, 2018	EMA	TETRAPHASE PHARMS
Aug. 27, 2018	FDA	TETRAPHASE PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infectious disease of abdomen	indication	128070006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.13	acidic
pKa2	8.11	acidic
pKa3	10.06	acidic
pKa4	11.96	acidic
pKa5	12.87	acidic
pKa6	13.5	acidic
pKa7	9.56	Basic
pKa8	8.88	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	June 3, 2020	RX	POWDER	INTRAVENOUS	8796245	Aug. 7, 2029	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
EQ 50MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	Aug. 27, 2018	RX	POWDER	INTRAVENOUS	8796245	Aug. 7, 2029	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	June 3, 2020	RX	POWDER	INTRAVENOUS	Aug. 27, 2023	NEW CHEMICAL ENTITY
EQ 50MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	Aug. 27, 2018	RX	POWDER	INTRAVENOUS	Aug. 27, 2023	NEW CHEMICAL ENTITY
EQ 100MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	June 3, 2020	RX	POWDER	INTRAVENOUS	Aug. 27, 2028	GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 50MG BASE/VIAL	XERAVA	TETRAPHASE PHARMS	N211109	Aug. 27, 2018	RX	POWDER	INTRAVENOUS	Aug. 27, 2028	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

None

External reference:

ID	Source
WK1NMH89VJ	UNII
C4723361	UMLSCUI
CHEMBL2219414	ChEMBL_ID
56951485	PUBCHEM_CID
CHEMBL1951095	ChEMBL_ID
D10369	KEGG_DRUG
288715	MMSL
34818	MMSL
017696	NDDF
DB12329	DRUGBANK_ID
2055907	RXNORM
C571179	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xerava	HUMAN PRESCRIPTION DRUG LABEL	1	71773-050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	NDA	30 sections
Xerava	HUMAN PRESCRIPTION DRUG LABEL	1	71773-100	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	NDA	30 sections